Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHASE GENOMICS, INC.
- Proposal award date
- 2020-09-17
- Contract end date
- 2021-02-28
- UEI
- TQ67ST6YELX5
- Solicitation number
- PA19-272
- Topic code
- 172
Research abstract
ABSTRACT
Cytogenetic testing is a cornerstone of clinical genetics diagnostics. However, even with state-of-the-art
methodologies, available clinical cytogenetic methods have a non-overlapping series of limitations. The
resolution of karyotyping is typically estimated to be in the 5-10 megabase pair (Mbp) range, limiting the ability
to definitively localize breakpoints. Fluorescence in situ hybridization (FISH) methods overcome some of these
limitations, but allow only one or in some cases a few loci to be interrogated at a time. Chromosomal microarray
analysis (CMA) offers important advantages over karyotyping and FISH, including applicability to virtually any
tissue, increased resolution, and semiautomated interpretation, but is unable to call balanced translocations,
inversions, complex rearrangements, and changes in ploidy. Thus, several complementary tests are typically
used in parallel or in sequence and this greatly inflates the costs and turnaround times of cytogenetic testing.
Proximity ligation methods such as chromosome conformation capture (3C, Hi-C) can be used to measure
physical and genetic distance between all pairs of loci simultaneously on a full-chromosome scale. This property
has been primarily applied to reconstructing end-to-end chromosome sequences for animals and plants.
However, this technology is extremely well suited to the detection of chromosomal aberrations using relatively
simple and ubiquitous sequencing tools and scalable computational analytics.
We propose to apply proximity ligation as a cytogenomic method to detect the breadth of chromosomal
aberrations at high resolution and low cost. This proposal outlines a path to a commercially available product
and service, which will establish a highly validated method for use in research and eventually in a diagnostic
setting. This will be accomplished by 1) designing an easy to use Hi-C protocol amenable to multiwell plate
handling, 2) building a robust automated platform to reproducibly call chromosomal aberrations from Hi-C data,
and 3) proving the validity and reproducibility of these methods on real world samples. The resulting kit and
software product will be a new cytogenomic method called Karyotyping by SequencingTM (KBS).NARRATIVE
Chromosomal abnormalities are a common cause of genetic disorders and infertility and their diagnosis can
inform clinical decision making. Several approaches have been developed to aid the detection of chromosomal
abnormalities, however none allow large-scale high-resolution aberration diagnosis. An efficient, comprehensive
diagnostic method is therefore needed to provide accurate data in the clinical genetics setting.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
13 SBIR/STTR records share this UEI (2016–2025). Reported award amounts total $13,717,161. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Agriculture
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards